TriSalus Life Sciences (NASDAQ:TLSI) Price Target Cut to $10.00 by Analysts at HC Wainwright

TriSalus Life Sciences (NASDAQ:TLSI) had its price objective lowered by stock analysts at HC Wainwright from $12.00 to $10.00 in a report released on Wednesday, Benzinga reports. The firm currently has a “buy” rating on the stock. HC Wainwright‘s target price would indicate a potential upside of 250.88% from the stock’s previous close.

A number of other research analysts have also weighed in on the company. Citigroup restated a “buy” rating on shares of TriSalus Life Sciences in a research report on Tuesday. Stifel Nicolaus set a $12.00 price target on TriSalus Life Sciences in a report on Wednesday, September 23rd. Wall Street Zen downgraded TriSalus Life Sciences from a “hold” rating to a “sell” rating in a research report on Saturday. Zacks Research raised shares of TriSalus Life Sciences to a “hold” rating in a research note on Thursday, September 10th. Finally, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of TriSalus Life Sciences in a research note on Wednesday, November 4th. Four analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $9.20.

TriSalus Life Sciences Trading Down 11.5%

TLSI stock opened at $2.85 on Wednesday. TriSalus Life Sciences has a one year low of $2.20 and a one year high of $7.95. The company’s fifty day moving average price is $4.21 and its 200-day moving average price is $4.34. The company has a debt-to-equity ratio of 5.05, a current ratio of 5.35 and a quick ratio of 4.97.

TriSalus Life Sciences (NASDAQ:TLSI) last posted its earnings results on Tuesday, November 10th. The company reported ($0.15) earnings per share for the quarter, missing the consensus estimate of ($0.13) by ($0.02). The company had revenue of $12.88 million for the quarter, compared to the consensus estimate of $14.02 million. Research analysts forecast that TriSalus Life Sciences will post -0.53 EPS for the current year.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of the company. State Street Corp lifted its holdings in shares of TriSalus Life Sciences by 86.3% in the 2nd quarter. State Street Corp now owns 610,963 shares of the company’s stock worth $2,780,000 after buying an additional 282,943 shares during the period. BlackRock Inc. bought a new position in shares of TriSalus Life Sciences during the 2nd quarter worth $12,099,000. Nantahala Capital Management LLC bought a new position in shares of TriSalus Life Sciences during the 2nd quarter worth $4,550,000. First Light Asset Management LLC increased its stake in shares of TriSalus Life Sciences by 29.3% during the second quarter. First Light Asset Management LLC now owns 6,552,491 shares of the company’s stock valued at $29,814,000 after buying an additional 1,485,664 shares during the period. Finally, Bank of New York Mellon Corp purchased a new position in shares of TriSalus Life Sciences during the second quarter valued at $507,000. 2.58% of the stock is currently owned by hedge funds and other institutional investors.

More TriSalus Life Sciences News

Here are the key news stories impacting TriSalus Life Sciences this week:

• Positive Sentiment: TriSalus reported third-quarter revenue growth of 11.3% to $12.9 million. Management outlined a 2026 revenue outlook of $46 million to $48 million, while TriNav Advance clearance was cited as a potential growth driver in 2027. Article: TriSalus outlines 2026 revenue outlook and growth drivers
• Neutral Sentiment: A short-interest report stated that short interest totaled zero shares as of November 10, offering no clear indication of notable short-selling pressure. TriSalus Life Sciences stock information
• Negative Sentiment: Quarterly results fell short of consensus: TriSalus reported a loss of $0.15 per share versus the expected $0.13 loss, and revenue of $12.88 million versus estimates of $14.02 million. The revenue shortfall and larger-than-expected loss may weigh on investor sentiment despite year-over-year growth. Article: TriSalus reports third-quarter results

About TriSalus Life Sciences

TriSalus Life Sciences is an oncology-focused healthcare company developing technologies and therapies for patients with liver and pancreatic tumors. The company combines medical devices, drug-delivery systems and immunotherapy programs to address tumors that may be difficult to treat with conventional approaches. Its core technology is Pressure-Enabled Drug Delivery (PEDD), a platform designed to improve the delivery of therapeutic agents directly to tumors through the arterial blood supply. TriSalus offers interventional oncology devices, including the TriNav Infusion System, which is designed to support localized delivery of treatments while helping limit drug diversion away from the targeted tumor.